Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen

Molecular Pharmacology

Volumn 76, Issue 5, 2009, Pages 946-956

  Deeken, John F ^a   Robey, Robert W ^b   Shukla, Suneet ^b   Steadman, Kenneth ^a   Chakraborty, Arup R ^e   Poonkuzhali, Balasubramanian ^c   Schuetz, Erin G ^d   Holbeck, Susan ^b   Ambudkar, Suresh V ^b   Bates, Susan E ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHRISTIAN MEDICAL COLLEGE   (India)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,7 PENTAHYDROXY 1,3,4,4A,5,11B HEXAHYDRO[1,3]DIOXOLO[4,5 J]PHENANTHRIDIN 6(2H) ONE; 17BETA 2,4 DIBROMO ESTRA 1,3,5(10) TRIENE 3,17 DIOL; 2 [METHYL(2 PYRIDIN 2 YLETHYL) AMINO]FLUOREN 9 ONE HYDROIODIDE; 5 AMINO 6 (7 AMINO 5,8 DIHYDRO 6 METHOXY 5,8 DIOXO 2 QUINOLINYL) 4 (2 HYDROXY 3,4 DIMETHOXYPHENYL) 3 METHYL 2 PYRIDINECARBOXYLICACID METHYLESTER; 5 HYDROXYPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; METHYL N (PYRIDINE 4 CARBONYLAMINO)CARBAMODITHIOATE; MITOXANTRONE; N (1 DECYLSULFANYL 3 HYDROXYPROPAN 2 YL) 3 (6 METHYL 2,4 DIOXO 1H PYRIMIDIN 5 YL)PROP 2 ENAMIDE; NSC 103054; NSC 24048; NSC 265473; NSC 349156; NSC 45384; NSC 636795; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DATA BASE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENETIC VARIATION; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTRATE SPECIFICITY; UNITED STATES;

EID: 70350245080     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.056192     Document Type: Article

References (38)

1. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, and Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/Pglycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95:2205-2214.
2. Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, Bates S, and Fojo T (1998) Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. Mol Pharmacol 54:802-814. (Pubitemid 28523172)
3. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, and Legrand O. (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896-7902. (Pubitemid 39587528)
4. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
5. de Bruin M, Miyake K, Litman T, Robey R, and Bates SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126. (Pubitemid 29492880)
6. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, and van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440-6449. (Pubitemid 350075034)
7. Deeken JF and Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674.
8. Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ, Close-Kirkwood S, Bauer N, Watanabe N, Hardenbol P, et al. (2007) Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 8:293-305. (Pubitemid 46477741)
9. Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, and Bates SE (2005) Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 235:84-92
10. Hardwick LJ, Velamakanni S, and van Veen HW (2007) The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol 151:163-174. (Pubitemid 46763043)
11. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, and Bates SE (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 1:696-702.
12. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, and Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616.
13. Jobson AG, Cardellina JH, 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, and Pommier Y (2007) Identification of a Bis-guanylhydrazone [4,4′- Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol 72:876-884.
14. Lee JK, Bussey KJ, Gwadry FG, Reinhold W, Riddick G, Pelletier SL, Nishizuka S, Szakacs G, Annereau JP, Shankavaram U, et al. (2003) Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol 4:R82.
15. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, and Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46:627-638. (Pubitemid 24334752)
16. Lee JS, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z, Altenberg G, and Bates SE (1997) Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem 65:513-526. (Pubitemid 27240917)
17. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, and Sparreboom A (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6:115-138. (Pubitemid 40613179)
18. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH Jr, et al. (2007) Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13:6788-6795. (Pubitemid 350206817)
19. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464. (Pubitemid 32695041)
20. McLachlan A, Kekre N, McNulty J, and Pandey S (2005) Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 10:619-630. (Pubitemid 40896667)
21. Minderman H, O'Loughlin KL, Pendyala L, and Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10:1826-1834. (Pubitemid 38435574)
22. Mizuarai S, Aozasa N, and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246. (Pubitemid 38240926)
23. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, and Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161-172. (Pubitemid 40884271)
24. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300. (Pubitemid 27413438)
25. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, and Greenberger LM (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58:5850-5858. (Pubitemid 29006428)
26. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, and Bates SE (2003) Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978. (Pubitemid 37533279)
27. Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, and Bates SE (2001) Overexpression of the ATPbinding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridolresistant human breast cancer cells. Clin Cancer Res 7:145-152. (Pubitemid 32110217)
28. Robey RW, Polgar O, Deeken J, To KW, and Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39-57. (Pubitemid 46452182)
29. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242-1246. (Pubitemid 38235589)
30. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, et al. (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127.
31. Shukla S, Robey RW, Bates SE, and Ambudkar SV (2006) The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45:8940-8951. (Pubitemid 44100690)
32. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112. (Pubitemid 20213250)
33. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, Wetzler M, Ross DD, and Baer MR (2004) Breast cancer resistance protein (BCRP/ MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 127:392-398. (Pubitemid 39536590)
34. Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129-137. (Pubitemid 39485685)
35. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, and Bates SE (1997) Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89:1505-1515. (Pubitemid 27441175)
36. Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, and Ambudkar SV (2007) Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther 6:3287-3296.
37. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, and Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19-28. (Pubitemid 36135683)
38. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al. (2001) The ABC transporter Bcrp1/ ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028-1034. (Pubitemid 32937383)